From the Department of Molecular Medicine, Scripps Research Institute, La Jolla, California 92037.
the Biomedical Gerontology Laboratory, Faculty of Human Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa 359-1192, Japan.
J Biol Chem. 2019 Mar 15;294(11):3909-3919. doi: 10.1074/jbc.RA118.005188. Epub 2019 Jan 17.
DNA polymerase θ () plays an important role in alternative nonhomologous end joining or microhomology-mediated end joining (alt-NHEJ/MMEJ). Here, we show that POLQ is not only required for MMEJ to repair DNA double-strand breaks (DSBs) generated by endonucleases such as I-SceI or Cas9, but is also needed for repair of DSBs derived from DNA nicks generated by Cas9 nickase. Consistently, we found that POLQ deficiency leads to sensitivity to topoisomerase inhibitors that cause DNA single-strand break (SSB) accumulation at replication forks and to ATR inhibitors that induce replication fork collapse. These studies support the function of POLQ in coping with replication stress and repairing DSBs upon fork collapse. POLQ overexpression is present in many cancer types and is associated with poor prognosis, including breast cancer regardless of BRCA1 status. We provide proof-of-concept evidence to support a novel cancer treatment strategy that combines POLQ inhibition with administration of topoisomerase or ATR inhibitors, which induces replication stress and fork collapse. Given the prevalence of POLQ overexpression in tumors, such strategy may have a significant impact on developing targeted cancer treatment.
DNA 聚合酶 θ()在非同源末端连接或微同源介导的末端连接(alt-NHEJ/MMEJ)中发挥重要作用。在这里,我们表明 POLQ 不仅是修复内切酶(如 I-SceI 或 Cas9)产生的 DNA 双链断裂(DSB)所必需的,而且对于 Cas9 核酸酶产生的 DNA 缺口修复也是必需的。一致地,我们发现 POLQ 缺陷导致对拓扑异构酶抑制剂的敏感性,这些抑制剂会导致复制叉处的 DNA 单链断裂(SSB)积累,以及对 ATR 抑制剂的敏感性,这些抑制剂会导致复制叉崩溃。这些研究支持 POLQ 在应对复制压力和修复叉崩溃时的 DSB 中的功能。POLQ 过表达存在于许多癌症类型中,与预后不良相关,包括乳腺癌,无论 BRCA1 状态如何。我们提供了支持新概念的证据,支持一种新的癌症治疗策略,即结合 POLQ 抑制剂与拓扑异构酶或 ATR 抑制剂的使用,这会诱导复制压力和叉崩溃。鉴于 POLQ 过表达在肿瘤中的普遍性,这种策略可能会对开发靶向癌症治疗产生重大影响。
DNA Repair (Amst). 2016-8
Nucleic Acids Res. 2023-3-21
Biochim Biophys Acta Mol Basis Dis. 2024-10
PLoS Genet. 2014-10-2
Science. 2023-8-11
MedComm (2020). 2024-10-31
DNA Repair (Amst). 2024-10
Cancer Genomics Proteomics. 2024
Science. 2018-3-16
Mol Cell. 2017-12-7
Nat Struct Mol Biol. 2017-12
Mutat Res. 2018-5
Nat Commun. 2016-12-13
Proc Natl Acad Sci U S A. 2016-11-29
Genes (Basel). 2016-9-21
Oncotarget. 2016-9-13